Janssen Pharmaceutical Inc.
1125 Trenton-Harbourton Road
Titusville
New Jersey
08560
United States
Tel: 609-730-2000
250 articles with Janssen Pharmaceutical Inc.
-
Owlstone Medical Enters into a Strategic Collaboration with Actelion to Develop a Breath-Based Test to Help Facilitate Early Detection of Pulmonary Hypertension
5/20/2019
Owlstone Medical announces a strategic collaboration with Actelion Pharmaceuticals Ltd, one of the Janssen Pharmaceutical Companies of Johnson & Johnson and a global leader in pulmonary arterial hypertension, to discover and validate a breath-based test to help facilitate the early diagnosis of pulmonary hypertension and its subtypes.
-
New Real-World Evidence Highlights Need for Interventions to Improve Outcomes for Patients Who Have Been Diagnosed with Major Depressive Disorder (MDD) and Suicide Ideation or Attempt
5/18/2019
Janssen Pharmaceutical Companies of Johnson & Johnson presented new real-world data at the American Psychiatric Association 2019 Meeting which suggest that, among adult patients with major depressive disorder, psychiatric treatment in the year prior to a diagnosis of suicide ideation or attempt is markedly low.
-
Janssen to Present Data from Robust Oncology Portfolio and Pipeline at the 2019 ASCO Annual Meeting, Including Best of ASCO Selections
5/15/2019
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the latest research from its robust oncology portfolio and pipeline to be presented at the 2019 American Society of Clinical Oncology Annual Meeting in Chicago from May 31 to June 4.
-
Janssen Demonstrates Strong Commitment to Inflammatory Bowel Disease with Data from 25 Abstracts Presented at the 2019 Digestive Disease Week Annual Meeting
5/14/2019
Phase 3 Data Evaluating STELARA® (ustekinumab) Efficacy and Safety in Patients with Moderate to Severe Ulcerative Colitis Featured in Two Oral Presentations
-
AstraZeneca announced a long-term collaboration deal with BenevolentAI, a UK-based company focused on combining computational medicine and advanced artificial intelligence.This deal only marks one of the most recent AI team-ups announced in the biopharma industry.
-
AMPLEXOR Announces 21st Annual BE THE EXPERT Training and Conference, Featuring Presenters from Iperion, Main 5, Guerbet, Janssen and LEO Pharma
5/2/2019
Focusing on ‘Make Transformation Happen’, AMPLEXOR’s annual event line-up of life sciences thought leaders will present strategies and best practices to transform processes and technologies, while combatting challenges in an ever-changing regulatory landscape
-
Janssen Announces Submission of New Drug Application to U.S. FDA For the First Monthly, Injectable, Two-Drug Regimen of Rilpivirine and Cabotegravir for Treatment of HIV
4/29/2019
If approved, the rilpivirine and cabotegravir regimen would be the first-ever long-acting injectable treatment for adults living with HIV
-
Arrowhead Begins Triple Combination Cohort in Chronic HBV Patients and Earns $25 Million Milestone Payment from Janssen
4/24/2019
Arrowhead Pharmaceuticals Inc. announced that it has begun dosing in a new triple combination cohort (cohort 12) that includes JNJ-3989 (formerly ARO-HBV) and additional undisclosed agents selected by Janssen Pharmaceuticals, Inc. in its ongoing Phase 1/2 study (AROHBV1001) in patients with chronic hepatitis B virus (HBV).
-
The survey showed that not surprisingly, patients by and large have negative views of the pharma industry when it comes to corporate responsibility and pricing -- mostly pricing.
-
Inside Look: Janssen’s HBV Asset Licensed From Arrowhead Could Become Treatment Franchise Corners...
4/17/2019
Janssen Pharmaceuticals presented data that showed its RNAi therapeutic candidate exhibited robust effects on the liver disease that takes the lives of more than 900,000 people annually. -
INVOKANA® (canagliflozin) Significantly Reduces the Risk of Renal Failure in Patients with Type 2 Diabetes and Chronic Kidney Disease in the Landmark Phase 3 CREDENCE Study
4/15/2019
INVOKANA® is the only medicine in nearly 20 years and the first diabetes medicine to demonstrate significant reduction in risk of renal failure, dialysis or kidney transplantation, and renal or cardiovascular death in this high-risk patient population
-
Janssen Presents Landmark Data From Positive Invokana Trial Halted Early at Australia Conference
4/15/2019
Janssen's Invokana could become the first diabetes medication to demonstrate reduction in progression to end-stage renal failure in Type 2 diabetes patients with chronic kidney disease. -
FDA Approves Janssen’s Balversa, First Targeted Therapy for Metastatic Urothelial Carcinoma
4/15/2019
The FDA's approval marks the first personalized treatment targeting susceptible FGFR genetic alterations for patients with metastatic bladder cancer. -
Janssen Presents New Data from First Phase 3 Trial of a Single-Tablet Regimen in a Rapid Initiation Model of Care Demonstrating Safety and Efficacy with SYMTUZA® through 48 Weeks
4/11/2019
High Proportion of Patients Achieve Undetectable Viral Loads after Rapidly Starting SYMTUZA®(1)
-
New data shows that patients are extremely satisfied with the medication. Data also showed that through 48 weeks, 84 percent of patients achieved undetectable viral loads, while 8 percent had virologic failures
-
More job cuts are coming to California life science companies. Charles River Labs and Janssen are both making cuts as they reprioritize their businesses, according to Worker Adjustment and Retraining Notifications filed with the state of California.
-
Janssen Submits Application for DARZALEX® (daratumumab) Combination Therapy to U.S. FDA for Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma
3/26/2019
First DARZALEX combination treatment regimen being pursued in the frontline setting for transplant eligible patients with multiple myeloma
-
New Phase 3 STELARA® (ustekinumab) Data Show Positive Results As Maintenance Therapy In Adults With Moderate To Severe Ulcerative Colitis
3/11/2019
One-year UNIFI data presented for the first time during plenary session at 14th Congress of the European Crohn's and Colitis Organisation
-
XARELTO® (rivaroxaban) Significantly Reduced Ischemic Stroke in Patients with Nonvalvular Atrial Fibrillation in Large, Real-World Meta-Analysis of Non-Vitamin K Antagonist Oral Anticoagulants (NOACs)
3/11/2019
Since its approval, more than 200,000 people have been evaluated in published real-world research for XARELTO® across all approved indications in the U.S.
-
Often, patients prefer oral medications over receiving an injection or infusion, but daily pills sometimes result in compliance problems. In the case of this combination injection, it would, if approved, require patients to visit a clinic or physician once a month for the shot.